A joint research team led by Dr. Akira Kunitomi, a former postdoctoral fellow at CiRA (currently a researcher at the Gladstone Institute of Cardiovascular Disease), and ID Pharma Co., Ltd., has uncovered the crucial role of oocyte-specific linker histone, H1FOO, in enhancing reprogramming efficiency and homogeneity to primed and naïve pluripotent states. The study is published in Stem Cell Reports.
